CD20 Stock Overview
Operates as a fashion company in Sweden, the rest of the Nordics, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nelly Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.27 |
| 52 Week High | SEK 2.74 |
| 52 Week Low | SEK 1.11 |
| Beta | 1.47 |
| 11 Month Change | 5.10% |
| 3 Month Change | -8.48% |
| 1 Year Change | 90.34% |
| 33 Year Change | -21.35% |
| 5 Year Change | -72.31% |
| Change since IPO | -93.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| CD20 | DE Specialty Retail | DE Market | |
|---|---|---|---|
| 7D | -5.4% | -0.5% | -1.3% |
| 1Y | 90.3% | 13.4% | 7.4% |
Return vs Industry: CD20 exceeded the German Specialty Retail industry which returned 11.3% over the past year.
Return vs Market: CD20 exceeded the German Market which returned 7.1% over the past year.
Price Volatility
| CD20 volatility | |
|---|---|
| CD20 Average Weekly Movement | 6.5% |
| Specialty Retail Industry Average Movement | 5.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CD20 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: CD20's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1936 | 151 | Helena Karlinder-Ostlundh | www.nellygroup.com |
Nelly Group AB (publ) operates as a fashion company in Sweden, the rest of the Nordics, and internationally. The company offers clothing, accessories, beauty products, and sportswear, as well as lingerie, and swimwear for women under the Nelly brand. It sells and markets its products online through Nelly.com and NLYman.com.
Nelly Group AB (publ) Fundamentals Summary
| CD20 fundamental statistics | |
|---|---|
| Market cap | €71.22m |
| Earnings (TTM) | €5.76m |
| Revenue (TTM) | €92.93m |
12.4x
P/E Ratio0.8x
P/S RatioIs CD20 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CD20 income statement (TTM) | |
|---|---|
| Revenue | SEK 1.08b |
| Cost of Revenue | SEK 515.00m |
| Gross Profit | SEK 562.50m |
| Other Expenses | SEK 495.70m |
| Earnings | SEK 66.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
| Earnings per share (EPS) | 2.23 |
| Gross Margin | 52.20% |
| Net Profit Margin | 6.20% |
| Debt/Equity Ratio | 0% |
How did CD20 perform over the long term?
See historical performance and comparison